Market research
4151.TSE Kyowa Kirin Co., Ltd
TSE JPY Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 1T
- P/E ratio
- 15.53
- Analyst target
- 2263.6365
- Dividend yield
- 2.8%
- Beta
- 0.22
Profile
Instrument facts
- Exchange
- TSE
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- JP3256000005
- Market cap
- 1T
- P/E ratio
- 15.53
- Analyst target
- 2263.6365
- Dividend yield
- 2.8%
- Beta
- 0.22
About
About Kyowa Kirin Co., Ltd
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis. It also develops KHK4083/AMG 451 rocatinlimab, which is in Phase III clinical trial for the treatment of moderate to severe atopic dermatitis and prurigo nodularis; KK8398 infigratinib, which is in Phase III clinical trial for the treatment of achondroplasia; OTL-203, which is in Phase III clinical trial for the treatment of hurler syndrome; KHK4951 tivozanib, which is in Phase II clinical trial for the treatment of diabetic macular edema and neovascular age-related macular degeneration; and OTL-201, which is in Phase II clinical trial for the treatment of sanfilippo syndrome type A. In addition, the company is involved in the development of KK2260 and KK2269, which are both in Phase I clinical trials for the treatment of advanced or metastatic solid tumors; KK2845, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; KK3910, which is in Phase I clinical trial for the treatment of essential hypertension; KK4277, which is in Phase I clinical trial for the treatment of systemic/cutaneous lupus erythematosus; and KK8123, which is in Phase I clinical trial for the treatment of X-linked hypophosphatemia. It has a partnership with La Jolla Institute for Immunology for research in disease areas; AstraZeneca for severe asthma treatment; and AMGEN for therapeutic drugs development. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in July 2019. Kyowa Kirin Co., Ltd. was incorporated in 1949 and is headquartered in Chiyoda, Japan. The company operates as a subsidiary of Kirin Holdings Company, Limited.
Research context
Kyowa Kirin Co., Ltd appears in PyInvesting’s Tokyo Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 4151.TSE discussion.
5 years, 7 months ago
Kyowa Kirin Co., Ltd is currently in a long term uptrend where the price is trading 29.0% above its 200 day moving average.
From a valuation standpoint, the stock is 91.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.7.
Kyowa Kirin Co., Ltd's total revenue rose by 5.0% to $84B since the same quarter in the previous year.
Its net income has dropped by 11.4% to $10B since the same quarter in the previous year.
Finally, its free cash flow fell by 58.5% to $5B since the same quarter in the previous year.
Based on the above factors, Kyowa Kirin Co., Ltd gets an overall score of 3/5.